Short-course regimens for latent tuberculosis: What is ready for prime time?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 25, Issue 5, 2007, Pages 297-299

  Burman, William J ^a  

^a DENVER PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; DRUG POTENCY; EDITORIAL; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; LIVER TOXICITY; MONOTHERAPY; PRICK TEST; SKIN TEST; TUBERCULOSIS;

EID: 34547624859     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13102263     Document Type: Editorial

References (18)

1. Shieh FK, Snyder G, Horsburgh CR, Bernardo J, Murphy C, Saukkonen JJ. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med. 2006;174:717-21.
2. Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med. 1999;159:295-300.
3. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med. 2003;168:443-7.
4. Van Zyl S, Marais BJ, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis. 2006;10:13-8.
5. Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza Kityo C, Nsubuga P, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001;15:2137-47.
6. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999;13:501-7.
7. Ji B, Truffot-Pernot C, LaCroix C, Raviglione MC, O'Brien RJ, Olliaro P, et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis. 1993;148:1541-6.
8. Gao XF, Wang L, Liu GJ, Wen J, Sun X, Xie Y, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis. 2006;10:1080-90.
9. Tortajada C, Martínez-Lacasa J, Sánchez F, Jiménez-Fuentes A, De Souza ML, García JF, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis. 2005;9:276-81.
10. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002;137:640-7.
11. Ijaz K, Jereb JA, Lambert LA, Bower WA, Spradling PR, McElroy PD, et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis. 2006;42:346-55.
12. Rivero A, López-Cortés L, Castillo R, Verdejo J, García A, Martínez-Marcos F, et al. Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH. Enferm Infecc Microbiol Clin. 2007;25:305-10.
13. Gordin FM, Cohn DL, Matts JP, Chaisson RE, O'Brien RJ. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis. 2004;39:561-5.
14. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997;337:801-8.
15. Gerjo MP, Herranz CR, Vaño D, García AJ, García M, Dimas JF. Pauta corta de isoniacida y rifampicina comparada con isoniacida para la infección latente de tuberculosis: ensayo clínico aleatorizado. Enferm Infecc Microbiol Clin. 2007;25:300-4.
16. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40:670-6.
17. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170:445-9.
18. Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006;173:922-6.